Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

← catalyst calendar

NCT03682068

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,246actual
Sites
222
Countries
Argentina, Australia, Brazil +19

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2018-09-27actualWhen the study began enrolling
Primary completion2026-06-01estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-06-01estimatedThe whole study's end, after follow-up
First posted2018-09-24actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-05-28actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Unresectable Locally Advanced Urothelial Cancer
  • Metastatic Urothelial Cancer

Interventions

  • Drug: Durvalumab — also filed as MEDI4736
  • Drug: Tremelimumab
  • Drug: Cisplatin + Gemcitabine
  • Drug: Carboplatin + Gemcitabine

Primary outcome

what the primary-completion date above is the date OF
Overall Survival (OS)
measured approximately 5 years

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed